6,562 results on '"Mancia, Giuseppe"'
Search Results
2. Cardio-Ankle Vascular Index and left ventricular mass as markers of nocturnal blood pressure fall in the general population
3. Effects of acute carotid baroreceptor stimulation on sympathetic nerve traffic in resistant and uncontrolled hypertension: a systematic review and meta-analysis
4. Reply to comment on “Cardio-Ankle Vascular Index and left ventricular mass as markers of nocturnal blood pressure fall in the general population”
5. Cost-effectiveness of single-pill and separate-pill administration of antihypertensive triple combination therapy: a population-based microsimulation study
6. Echocardiographic Phenotypes of Subclinical Organ Damage: Clinical and Prognostic Value in the General Population. Findings from the Pamela Study
7. New-onset aortic dilatation in the population: a quarter-century follow-up
8. 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension
9. Anthropometric Measures of Adiposity as Markers of Kidney Dysfunction: A Cross-Sectional Study
10. Diabetogenic Effects of Antihypertensive Drugs and Statins
11. Adherence to antidiabetic drug therapy and reduction of fatal events in elderly frail patients
12. Respiratory patterns and baroreflex function in heart failure
13. Risk of Dementia During Antihypertensive Drug Therapy in the Elderly
14. The current best drug treatment for hypertensive heart failure with preserved ejection fraction
15. The impact of the COVID-19 Pandemic on hypertension phenotypes (ESH ABPM COVID-19 study)
16. Long-term increase in serum uric acid and its predictors over a 25 year follow-up: Results of the PAMELA study
17. Abstract 13852: Sex Differences in Blood Pressure Reduction and Cardiovascular Outcomes in Patients With Resistant Hypertension Undergoing Radiofrequency Renal Denervation: Global SYMPLICITY Registry DEFINE
18. Relationships between sympathetic markers and heart rate thresholds for cardiovascular risk in chronic heart failure
19. Reproducibility of blood pressure phenotypes identified by office and ambulatory blood pressure in treated hypertensive patients. Data from the PHYLLIS study
20. Correction to: Diabetes and Microcirculation
21. Diabetogenic Effects of Antihypertensive Drugs and Statins
22. COVID-19 and Antihypertensive Treatment
23. Coffee consumption, clinic, 24-hour and home blood pressure. Findings from the PAMELA study
24. Risk prediction by ambulatory blood pressure monitoring in non-diabetic and diabetic patients: better than office measurements
25. Habitual Regular Coffee Consumption And Arterial Stiffness -Data From The 3rd Pamela Survey
26. Cardiovascular Outcomes in Hypertension-Treated Patients With Peripheral Artery Disease: The VALUE Trial
27. Impact of seasonal blood pressure changes on visit-to-visit blood pressure variability and related cardiovascular outcomes
28. ACHIEVED SYSTOLIC BLOOD PRESSURE BELOW 130 MMHG PRESERVES KIDNEY FUNCTION IN DIABETIC AND NON-DIABETIC HYPERTENSIVE PATIENTS WITHOUT CARDIAC HYPERTROPHY
29. ACHIEVED SYSTOLIC BLOOD PRESSURE BELOW 130 MMHG PRESERVES KIDNEY FUNCTION IN HIGH-RISK HYPERTENSIVE PATIENTS WITHOUT CARDIAC HYPERTROPHY BUT WITH PROTEINURIA
30. POOLED, LONG-TERM ANALYSIS OF THE GLOBAL SYMPLICITY CLINICAL TRIAL PROGRAM OF RADIOFREQUENCY RENAL DENERVATION FOR THE TREATMENT OF UNCONTROLLED HYPERTENSION
31. RENAL DENERVATION RESULTS IN SUBSTANTIAL NOCTURNAL BP REDUCTION IN PATIENTS WITH A REVERSED DIPPING PATTERN
32. THREE-YEAR NIGHTTIME BLOOD PRESSURE REDUCTIONS AFTER RADIOFREQUENCY RENAL DENERVATION IN PATIENTS WITH UNCONTROLLED HYPERTENSION AND CHRONIC KIDNEY DISEASE
33. ANTIHYPERTENSIVE DRUG THERAPY AND RISK OF DEMENTIA: REAL-WORLD EVIDENCE FROM A LARGE OLD POPULATION
34. Rationale for the Inclusion of β-Blockers Among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines
35. THE IMPACT OF THE COVID-19 PANDEMIC ON OFFICE AND 24-HOUR BLOOD PRESSURE PHENOTYPES (ESH ABPM COVID-19 STUDY)
36. COST-EFFECTIVENESS OF SINGLE-PILL AND SEPARATE-PILL ADMINISTRATION OF ANTIHYPERTENSIVE TRIPLE-COMBINATION THERAPY: A POPULATION-BASED MICROSIMULATION STUDY
37. HIGHER BASELINE SYSTOLIC BLOOD PRESSURE IS ASSOCIATED WITH GREATER BLOOD PRESSURE REDUCTIONS FOLLOWING RADIOFREQUENCY RENAL DENERVATION IN A POOLED COHORT OF OVER 3900 PATIENTS
38. Beta-blocker bashing and downgrading in hypertension management: a fashionable trend representing a matter of concern
39. Correction: New-onset aortic dilatation in the population: a quarter-century follow-up
40. New antidiabetic therapy and HFpEF: light at the end of tunnel?
41. Cardiovascular Risk Reduction After Renal Denervation According to Time in Therapeutic Systolic Blood Pressure Range
42. Secondary Hypertension and Cardiovascular Risk: An Overview
43. Home Blood Pressure and Preclinical Organ Damage
44. Guidelines for Home Blood Pressure Monitoring
45. Correction to: Diabetes and Microcirculation
46. Cumulative Systolic Blood Pressure Load and Cardiovascular Risk in Patients With Diabetes
47. Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines: Comparisons, Reflections, and Recommendations
48. Effects of glucose and blood pressure reduction on subclinical cardiac damage: Results from ADVANCE
49. Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy
50. Uric Acid, Hypertensive Phenotypes, and Organ Damage: Data from the Pamela Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.